Pseudoparticle neutralization assay for detecting ebola- neutralizing antibodies in biosafety level 2 settings.
作者信息
Chin Alex W H, Perera Ranawaka A P M, Guan Yi, Halfmann Peter, Kawaoka Yoshihiro, Peiris Malik, Poon Leo L M
机构信息
Centre of Influenza Research School of Public Health and.
Department of Pathobiological Sciences School of Veterinary Medicine University of Wisconsin Madison, WI.
出版信息
Clin Chem. 2015 Jun;61(6):885-6. doi: 10.1373/clinchem.2015.238204. Epub 2015 Mar 31.
Abstract
摘要
相似文献
1
Pseudoparticle neutralization assay for detecting ebola- neutralizing antibodies in biosafety level 2 settings.
Clin Chem. 2015 Jun;61(6):885-6. doi: 10.1373/clinchem.2015.238204. Epub 2015 Mar 31.
2
High degree of correlation between Ebola virus BSL-4 neutralization assays and pseudotyped VSV BSL-2 fluorescence reduction neutralization test.
J Virol Methods. 2018 Apr;254:1-7. doi: 10.1016/j.jviromet.2018.01.003. Epub 2018 Jan 31.
3
Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu).
J Infect Dis. 2013 Jul 15;208(2):299-309. doi: 10.1093/infdis/jit162. Epub 2013 Apr 12.
4
Scalable, semi-automated fluorescence reduction neutralization assay for qualitative assessment of Ebola virus-neutralizing antibodies in human clinical samples.
PLoS One. 2019 Aug 27;14(8):e0221407. doi: 10.1371/journal.pone.0221407. eCollection 2019.
5
Why Japan imported Ebola ahead of the 2020 Olympics.
Nature. 2019 Oct;574(7778):306-307. doi: 10.1038/d41586-019-03103-4.
6
Validating the Inactivation Effectiveness of Chemicals on Ebola Virus.
Methods Mol Biol. 2017;1628:251-257. doi: 10.1007/978-1-4939-7116-9_20.
7
Development of a micro-neutralization assay for ebolaviruses using a replication-competent vesicular stomatitis hybrid virus and a quantitative PCR readout.
Vaccine. 2017 Oct 4;35(41):5481-5486. doi: 10.1016/j.vaccine.2017.03.019. Epub 2017 Apr 17.
8
Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP.
J Infect Dis. 2015 Oct 1;212 Suppl 2:S372-8. doi: 10.1093/infdis/jiv303. Epub 2015 Aug 1.
9
[Therapeutic use of immune sera. Ebola survivors as lifesavers?].
MMW Fortschr Med. 2014 Nov 6;156(19):6.
10
Quantification of Filovirus Glycoprotein-Specific Antibodies.
Methods Mol Biol. 2017;1628:309-320. doi: 10.1007/978-1-4939-7116-9_25.
引用本文的文献
1
IgY antibodies against Ebola virus possess post-exposure protection in a murine pseudovirus challenge model and excellent thermostability.
PLoS Negl Trop Dis. 2021 Mar 12;15(3):e0008403. doi: 10.1371/journal.pntd.0008403. eCollection 2021 Mar.
2
Generation of MERS-CoV Pseudotyped Viral Particles for the Evaluation of Neutralizing Antibodies in Mammalian Sera.
Methods Mol Biol. 2020;2099:117-126. doi: 10.1007/978-1-0716-0211-9_10.
3
Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection.
Sci Rep. 2017 Mar 30;7:45552. doi: 10.1038/srep45552.
本文引用的文献
1
Emergence of Zaire Ebola virus disease in Guinea.
N Engl J Med. 2014 Oct 9;371(15):1418-25. doi: 10.1056/NEJMoa1404505. Epub 2014 Apr 16.
2
Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013.
Euro Surveill. 2013 Sep 5;18(36):pii=20574. doi: 10.2807/1560-7917.es2013.18.36.20574.
3
Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin.
PLoS One. 2009 Nov 20;4(11):e7918. doi: 10.1371/journal.pone.0007918.
4
Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses.
J Virol. 2003 Jan;77(2):1069-74. doi: 10.1128/jvi.77.2.1069-1074.2003.
Zotero 插件